RG6538 / J&J, Roche, Genentech - LARVOL DELTA

A Phase 1 Study of P-BCMA-ALLO1, a Non-Viral, Allogeneic BCMA Directed CAR-T in Relapsed/Refractory Multiple Myeloma (RRMM): Results from Optimized Lymphodepletion Cohort (Arm C) (TCT-ASTCT-CIBMTR 2025) - P1 | "Here, we present data on pts treated in Arm C, with approximately 2 x 10 6 P-BCMA-ALLO1 cells/kg, after completing the arm C 3-day LD regimen (cyclophosphamide 750 mg/m 2 /day and fludarabine 30 mg/m 2 /day), which has been selected for phase 1b expansion...The ORR was 86% in the subset of 7 pts who received both prior BCMA-targeted therapy, as well as talquetamab... P-BCMA-ALLO1 is a non-viral, T SCM -rich, allogeneic BCMA-targeting CAR-T rapidly delivered to all eligible pts without the need for bridging therapy. P-BCMA-ALLO1 demonstrates a promising ORR and favorable safety profile, regardless of prior exposure to BCMA-targeted therapy. The P-BCMA-ALLO1-001 (NCT04960579) clinical trial is actively enrolling pts."

P1 data • Anemia • CNS Disorders • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Leukopenia • Movement Disorders • Multiple Myeloma • Neutropenia • Oncology • Parkinson's Disease • Thrombocytopenia • B2M • CD38

A Phase 1 Study of P-BCMA- ALLO1, a Non-viral, Allogeneic BCMA Directed CAR-T in Relapsed/Refractory Multiple Myeloma (RRMM) (IMW 2024) - P1 | "These "P" LD arms include: P1 - cyclophosphamide (cy) 500 mg/m²/day + fludarabine (flu) 30 mg/m²/day, P1.5 - cy 750 mg/m²/day + flu 30 mg/m²/day, and P2 - cy 1000 mg/m²/day + flu 30 mg/m²/day, for 3 days. In summary, P-BCMA-ALLO1 is a well-tolerated allogeneic CAR-T that is available "on-demand" and demonstrates low rates of CRS and ICANS. Enrollment is ongoing and updated safety and efficacy data will be presented at the meeting."

IO biomarker • P1 data • Anemia • Febrile Neutropenia • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Leukopenia • Multiple Myeloma • Neutropenia • Oncology • Thrombocytopenia • B2M

TSCM-predominant allogeneic anti-BCMA CAR-T therapy for relapsed/refractory multiple myeloma: preclinical characterization and interim results from a phase 1 trial. (PubMed, Nat Commun) - P1 | "Here, we present the characterization and interim Phase I data for P-BCMA-ALLO1, a TSCM-predominant allogeneic CAR-T therapy targeting BCMA in heavily pretreated relapsed/refractory multiple myeloma...These data suggest that a TSCM cellular phenotype may offer significant advantages in efficacy, safety, and cellular persistence in the context of allogeneic CAR-T therapy. Clinical trial: NCT04960579."

Journal • P1 data • Preclinical • Hematological Malignancies • Multiple Myeloma • Oncology • CD8

P-BCMA-ALLO1-001: P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma (clinicaltrials.gov) - P1 | N=275 | Active, not recruiting | Sponsor: Poseida Therapeutics, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Hematological Malignancies • Multiple Myeloma • Oncology

Solid tumor patients require higher cyclophosphamide (cy) dose than multiple myeloma (MM) patients to achieve adequate lymphodepletion (LD) necessary to enable allogeneic CAR-T expansion (AACR 2024) - P1 | "LD arm S used cy 300 mg/m2 + fludarabine (flu) 30 mg/m2 × 3 days, followed by CAR-T. Increasing cy dose to 500 or 1,000 mg/m2 improves CK for P-BCMA-ALLO1 pts due to enhanced LD depth. For P-MUC1C-ALLO1 pts, increasing cy to 500 does not improve LD depth or CK compared to 300. This difference suggests the need for higher LD doses in ST pts than MM pts to achieve optimal CK."

CAR T-Cell Therapy • Clinical • Hematological Malignancies • Multiple Myeloma • Oncology • Solid Tumor • IL15 • MUC1

Clinical activity of P-BCMA-ALLO1, a B-cell maturation antigen (BCMA) targeted allogeneic chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed refractory multiple myeloma (RRMM) patients (pts) following progression on prior BCMA targeting therapy (AACR 2024) - "These pts were treated in arms P1 (LD: cyclophosphamide (cy) 500 mg/m2 + fludarabine (flu) 30 mg/m2 X 3 days) or arm P2 (LD: cy 1000 mg/m2 + flu 30 mg/m2 X 3 days) at a P-BCMA-ALLO1 dose of > 2 X 106 to <6 X 106 cells/kg. The median pt age was 62 years and median prior lines of therapy was 10...One pt who had previously received both teclistamab and CAR-T achieved VGPR. In conclusion, P-BCMA-ALLO1 is an allogeneic CAR-T that is available "on-demand" with activity in RRMM pts who have progressed following prior BCMA targeted CAR-T and TCE. In conclusion, P-BCMA-ALLO1 is an allogeneic CAR-T that is available "on-demand" with activity in RRMM pts who have progressed following prior BCMA targeted CAR-T and TCE. We believe this is the first such report of an allogeneic CAR-T showing clinical activity in such a pt population with high unmet need. Enrollment is continuing and updated data will be presented at the meeting."

CAR T-Cell Therapy • Clinical • Hematological Malignancies • Multiple Myeloma • Oncology

Enhanced potency of BCMA/CD19 dual-targeting allogeneic CAR-T cells for relapsed/ refractory multiple myeloma with 4-1BB/TACI intracellular domains (AACR 2025) - P1 | "Furthermore, anti-CD19 CAR-T cells given after high-dose melphalan and stem cell transplantation have shown to improve patient survival and can eliminate MM progenitor cells that are resistant to BCMA-directed CAR-T cells.P-BCMACD19-ALLO1 is a fully allogeneic CAR-T therapy designed to target BCMA and CD19...TSCM -rich CAR-Ts, including our BCMA-targeting allogeneic P-BCMA-ALLO1 CAR-T for RRMM (NCT04960579), have shown favorable efficacy and safety in the clinic.To develop P-BCMACD19-ALLO1, we constructed the BCMA CAR using two fully human, single-domain, heavy-chain variable domains (VHs) that independently bind BCMA and are joined together by a G4S linker in tandem. The tandem anti-BCMA VHs binds to all clinical escape mutants, including teclistamab-resistant R27P mutation...P-BCMACD19-ALLO1 also demonstrates potent, in vitro killing of tumor cells expressing R27P, P33Del, P33S and S30Del escape mutants. Lastly, P-BCMACD19-ALLO1 effectively eliminates primary bone..."

CAR T-Cell Therapy • IO biomarker • Hematological Malignancies • Multiple Myeloma • Oncology • B2M • CD81 • DHFR • TNFA

P-BCMA-ALLO1-001: P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma (clinicaltrials.gov) - P1 | N=275 | Recruiting | Sponsor: Poseida Therapeutics, Inc. | Trial completion date: Dec 2039 ➔ Mar 2042 | Trial primary completion date: Dec 2027 ➔ Mar 2029

Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

Early Safety Results of P-BCMA-ALLO1, a Fully Allogeneic Chimeric Antigen Receptor T-Cell (CAR-T), in Patients with Relapsed / Refractory Multiple Myeloma (RRMM) (ASH 2023) - P1 | "We are currently dosing patients in arm S (Cyclophosphamide (Cy) 300 mg/m2 + Fludarabine (Flu) 30 mg/m2 X 3 days), arm P1 (Cy 500 mg/m2 + Flu 30 mg/m2 X 3 days), arm P2 (Cy 1,000 mg/m2 + Flu 30 mg/m2 X 3 days) and arm C (multiple P-BCMA-ALLO1 doses following Cy 300 mg/m2 + Flu 30 mg/m2 X 3 days). P-BCMA-ALLO1 is a non-viral transposon-generated allogeneic "off-the-shelf" CAR-T that is rapidly available for administration and well tolerated in a heavily pretreated RRMM patient population with minimal CRS/ICANS risk. Updated results including safety, preliminary efficacy, and selected biomarkers will be presented at the American Society of Hematology 2023 meeting."

CAR T-Cell Therapy • Clinical • IO biomarker • Anemia • Constipation • Gastroenterology • Gastrointestinal Disorder • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Inflammation • Leukopenia • Multiple Myeloma • Neutropenia • Oncology • B2M

Enhanced Potency of BCMA/CD19 Dual-Targeting Allogeneic CAR-T Cells for Relapsed/ Refractory Multiple Myeloma with 4-1BB/TACI Intracellular Domains (ASH 2024) - P1 | "Furthermore, it has been reported that anti-CD19 CAR-T cells given after high-dose melphalan and stem cell transplant improve patient survival and can eliminate MM progenitor cells that are resistant to BCMA-directed CAR-T cells in ex vivo assays.P-BCMACD19-ALLO1 is a fully allogeneic CAR-T therapy expressing two full-length CARs targeting BCMA and CD19, each with an optimized intracellular domain (ICD) for enhanced potency...Clinical data from Poseida and others have demonstrated safety and efficacy advantages associated with TSCM CAR-T, including for P-BCMA-ALLO1, our BCMA-targeting allogeneic CAR-T for RRMM (NCT04960579).We show that replacing the standard 4-1BB co-stimulatory domain with an ICD derived from the tumor necrosis factor (TNF) receptor family member transmembrane activator and CAML interactor (TACI) enhances in vivo potency against a CD19 +/BCMA+ xenograft model when TACI is placed in the CD19 CAR...P-BCMACD19-ALLO1 CAR-T cells demonstrated potent in..."

CAR T-Cell Therapy • IO biomarker • Hematological Malignancies • Multiple Myeloma • Oncology • B2M • DHFR • TNFA

A Phase 1 Study of P-BCMA-ALLO1, a Non-Viral, Allogeneic BCMA Directed CAR-T in Relapsed/Refractory Multiple Myeloma (RRMM): Results from Optimized Lymphodepletion Cohort (ASH 2024) - P1 | "Here, we present data on pts treated with a dose of approximately 2 x 106 cells/kg, after completing a 3-day LD regimen (cyclophosphamide 750 mg/m2/day and fludarabine 30 mg/m2/day)...62% had undergone prior BCMA-targeted CAR-T and/or T cell engager (TCE) therapy, 29% had previously received both a BCMA-targeted CAR-T and/or TCE and Talquetamab...The P-BCMA-ALLO1-001 clinical trial is actively enrolling pts. Updated safety and efficacy data will be presented at ASH 2024."

IO biomarker • P1 data • Anemia • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Leukopenia • Multiple Myeloma • Neutropenia • Oncology • Thrombocytopenia • CD38 • SDC1

P-CD19CD20-ALLO1: Potent Fully Allogeneic CAR-T Therapy Targeting CD19 and CD20 with Superior Efficacy over Single-Target Products (ASH 2024) - P1 | "Clinical data from Poseida and others have demonstrated safety and efficacy advantages associated with TSCM CAR-T, including for P-BCMA-ALLO1, our BCMA-targeting allogeneic CAR-T for Relapsed/Refractory Multiple Myeloma (NCT04960579). P-CD19CD20-ALLO1 CAR-T cells were superior to the CD19-targeting CAR-T product. P-CD19CD20-ALLO1, a dual-targeting, fully allogeneic TSCM-rich CAR-T product for CD19 and CD20-positive B-cell malignancies, demonstrates robust antigen-specific activity against DLBCL and CLL models and outperforms its single-targeting counterparts even in the presence of only a single antigen on target cells."

Clinical • IO biomarker • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Multiple Myeloma • Oncology • B2M • CD19 • FASLG • GZMA • IFNG

P-CD19CD20-ALLO1: A TSCM-PREDOMINANT ALLOGENEIC CAR-T THERAPY TARGETING CD19 and CD20 FOR B-CELL MALIGNANCIES DEMONSTRATES ADVANTAGES BEYOND PREVENTING ANTIGEN ESCAPE (ICML 2025) - P1 | "Clinical data from TSCM-rich CAR-T P-BCMA-ALLO1, our BCMA-targeting allogeneic CAR-T for R/R multiple myeloma (NCT04960579), have demonstrated favorable safety and efficacy, likely related at least in part to the undifferentiated CAR-T. P-CD19CD20-ALLO1, a dual-targeting, fully allogeneic TSCM-rich CAR-T product for CD19 and CD20-positive B-cell malignancies, demonstrates robust antigen-specific activity against diffuse large B cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL) models as well as the phenotype and function associated with TSCM. P-CD19CD20-ALLO1 is currently being investigated in an open-label, multicenter Phase 1 study in subjects with R/R B cell malignancies (NCT06014762) and for autoimmune diseases."

IO biomarker • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • B2M • CD19

P-BCMA-ALLO1 Is Safe and Efficacious in R/R Multiple Myeloma (OncLive) - P1 | N=231 | NCT04960579 | Sponsor: Poseida Therapeutics, Inc. | "P-BCMA-ALLO1 demonstrated activity with a compelling safety profile in patients with relapsed/refractory multiple myeloma, according to findings from arm C of a phase 1 trial (NCT04960579) presented at the 2025 Transplantation & Cellular Therapy Meetings. Patients who received the investigational off-the-shelf, allogeneic CAR T-cell therapy (n = 32) achieved an overall response rate (ORR) of 88%, including 100% in patients who had no prior BCMA-targeted therapy (n = 16) and 75% in patients who had received at least 1 prior anti-BCMA treatment (n = 16). Patients who had received prior BCMA-targeted and GPRC5D-targeted therapy (talquetamab [Talvey]; n = 9) experienced an ORR of 78%."

P1 data • Multiple Myeloma

Clinical Activity of P-BCMA-ALLO1, an Allogeneic BCMA Targeting CAR-T, in Patients with Relapsed Refractory Multiple Myeloma (RRMM) and Extramedullary Disease (TCT-ASTCT-CIBMTR 2025) - P1 | "Pts receive a 3-day LD regimen of fludarabine 30 mg/m 2 /day plus cyclophosphamide 300 mg/m 2 /day (arm S), 500 mg/m 2 /day (arm A), 1000 mg/m 2 /day (arm B) or 750 mg/m 2 /day (arm C). P-BCMA-ALLO1 when administered with optimized LD in arm C is a safe and effective therapy for pts with EMD. We will continue to enroll pts with EMD to further assess P-BCMA-ALLO1 activity in this high-risk subgroup. Updated safety and efficacy data will be presented at the conference."

Clinical • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Multiple Myeloma • Oncology • B2M • CD38

Poseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1…at the 66th American Society of Hematology (ASH) Annual Meeting (PRNewswire) - P1/1b | N=231 | NCT04960579 | Sponsor: Poseida Therapeutics, Inc. | "The data showed a 91% overall response rate (ORR) in Arm C (an optimized lymphodepletion arm), including a 100% ORR in B-cell maturation antigen (BCMA)-naïve patients, and an 86% ORR in those who had received at least one prior BCMA- and/or G protein-coupled receptor class C group 5 member D (GPRC5D)-targeting treatment modality, along with differentiated safety results with no dose-limiting toxicities, low rates of cytokine release syndrome (CRS) and immune effector cell neurotoxicity syndrome (ICANS)....New profiling of patient responses from Arm C are included in the ASH poster presentation. The data from this analysis show consistent P-BCMA-ALLO1 cellular expansion and persistence across different subgroups, including patients that are typically more challenging to treat."

P1 data • Multiple Myeloma

Poseida Therapeutics to Present Clinical and Preclinical Data on Investigational Allogeneic CAR-T Cell Therapies at SITC 2024 and ASH 2024 (PRNewswire) - "Poseida Therapeutics...announced new preclinical data on allogeneic CAR+TCR-T cells rich in stem cell memory T cells (T_SCM), along with platform enhancements aimed at enhancing potency and improving targeting of solid tumors, will be presented at the Society for Immunotherapy of Cancer (SITC)...Additionally, the Company announced presentations at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition, which will be held December 7-10 in San Diego. To further characterize compelling emerging P-BCMA-ALLO1 clinical data, additional profiling of patient responses from the optimized lymphodepletion arm (Arm C) of the P-BCMA-ALLO1 Phase 1 study, along with data first presented at the 21st International Myeloma Society (IMS) Annual Meeting will be highlighted as a poster presentation. In addition, preclinical data from the ongoing Phase 1 trial of P-CD19CD20-ALLO1 in patients with B-cell malignancies will be delivered as a poster presentation."

Clinical data • Preclinical • Hematological Malignancies • Multiple Myeloma • Oncology

Poseida Therapeutics Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical…Pipeline (PRNewswire) - "Poseida Therapeutics...announced plans to share progress across its clinical- and earlier-stage pipeline of differentiated T stem cell memory cells (TSCM)-rich allogeneic CAR-T therapies in oncology and autoimmune diseases during a virtual R&D Day to be held today at 10:00am ET / 7:00am PT....Poseida will provide an overview of recently reported interim Phase 1 results for P-BCMA-ALLO1, its lead CAR-T program targeting BCMA for the treatment of multiple myeloma. New preclinical data suggest that P-BCMA-ALLO1 effectively targets mutations that are known to arise in patients with relapse after prior anti-BCMA therapies. P-BCMA-ALLO1 is part of Poseida's collaboration with Roche and is currently enrolling a Phase 1b dose expansion study, which will be outlined in the presentation...P-CD19CD20-ALLO1 is the Company's first dual CAR-T....A Phase 1 clinical trial is enrolling patients with selected B-cell malignancies, with initial clinical data anticipated in 2025."

Clinical data • Hematological Malignancies • Multiple Myeloma • Oncology

Bhagirathbhai R. Dholaria, MD, on Evaluating Allogeneic CAR-T P-BCMA-ALLO1 in R/R Multiple Myeloma (CGTLive) - "Following the conference, CGTLive got in touch with trial investigator Bhagirathbhai R. Dholaria, MD...to learn more about the data. Dholaria explained what differentiates P-BCMA-ALLO1 from current FDA-approved CAR-T therapies for MM, pointing out that it is allogeneic rather than autologous and that it is engineered with a nonviral gene-editing approach. Afterwards he spoke about the promising safety and efficacy results, highlighting the nonoccurrence of graft versus host disease in the treated patients and the 91% overall response rate in the enhanced lymphodepletion arm."

Video

Poseida Therapeutics Hosts Cell Therapy R&D Day Highlighting Its Innovative...Preclinical Pipeline (PRNewswire) - "New preclinical data demonstrate P-BCMACD19-ALLO1's potential....Effectively eliminated primary human CD81+CD19+ multiple myeloma progenitor cells from patient bone marrow samples, addressing cells associated with relapse where BCMA-only targeted therapies were ineffective; Demonstrated ability of P-BCMACD19-ALLO1 and P-BCMA-ALLO1 to kill tumor cells expressing known mutant forms of BCMA, which are linked to relapse in patients treated with autologous CAR-T and bispecific T cell engager therapies directed at BCMA."

Preclinical • Hematological Malignancies • Multiple Myeloma • Oncology

Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies (GlobeNewswire) - "Roche...announced today that it has entered into a definitive merger agreement to acquire Poseida Therapeutics, Inc....Based in San Diego, California, Poseida’s R&D portfolio includes pre-clinical and clinical-stage off-the-shelf (also referred to as allogeneic) CAR-T therapies across several therapeutic areas including haematological malignancies, solid tumours, and autoimmune disease, as well as manufacturing capabilities and technology platforms....Under the terms of the merger agreement, Roche will promptly commence a tender offer to acquire all of the outstanding shares of Poseida common stock at a price of US $9.00 per share in cash at closing plus a non-tradeable CVR to receive certain milestone payments of up to an aggregate of US $4.00 per share in cash, representing a total equity value of approximately US $1.0 billion at closing and representing a total deal value of up to US $1.5 billion."

M&A • Hematological Malignancies • Multiple Myeloma • Oncology • Solid Tumor

P-BCMA-ALLO1 May Be Safe, Rapid, and Active Allogeneic CAR T-Cell Therapy in Pretreated R/R Myeloma (OncLive) - "'We are especially impressed with the higher lymphodepletion overall response rates, even among the patient who had prior exposure to other CAR T cell therapy or bispecific therapies,' presenting study author Bhagirathbhai Dholaria, MBBS...As an 'off-the-shelf' therapy, P-BCMA-ALLO1 could provide a novel therapeutic avenue to treat patients with rapidly progressing multiple myeloma who are ineligible for autologous therapies, Dholaria explained. He added that, 'In United States, we are now in a post-BCMA era when it comes to relapsed/refractory myeloma, and this is an area [where] normal therapies are urgently needed.'"

Media quote

Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients (PRNewswire) - "'The compelling and differentiated results from the optimized lymphodepletion arms of the ongoing Phase 1 trial of P-BCMA-ALLO1 showed deep responses and a high response rate in patients with heavily pre-treated relapsed or refractory multiple myeloma, regardless of prior exposure to B-cell maturation antigen (BCMA)-targeting therapy....Such patients treated in the current trial of P-BCMA ALLO1 would not have qualified for standard of care autologous CAR T therapy,' said Bhagirathbhai R. Dholaria...'All patients in the Phase 1 trial have been treated quickly once enrolled, with no waiting for manufacturing, with no need for apheresis or bridging therapy, demonstrating key advantages of allogeneic CAR-T cell therapy.'"

Media quote

Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients (PRNewswire) - P1/1b | N=231 | NCT04960579 | Sponsor: Poseida Therapeutics, Inc. | "The new clinical data were presented today in an oral session at the 21st International Myeloma Society (IMS) Annual Meeting....As of September 6, 2024, 72 unique patients were enrolled as an intent-to-treat (ITT) population....The ORR across all four study arms was 54%; 11% of patients achieved a complete response (CR) or a stringent complete response (sCR), and 33% achieved a very good partial response or higher (VGPR+)....Results from 23 study participants in Arm C were highlighted in the oral session at IMS....An ORR of 91%, with a 100% ORR in BCMA-naïve patients, an 86% ORR in those who had received at least one prior BCMA-targeting treatment (all had received prior CAR-T and/or TCE), and an 86% ORR in those who had received at least one prior BCMA-targeting treatment and/or talquetamab. 22% achieved a CR or an sCR. 48% achieved VGPR+."

P1 data • Multiple Myeloma

Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-ALLO1 to Treat Relapsed/Refractory Multiple Myeloma (PRNewswire) - "Poseida Therapeutics, Inc...announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to P-BCMA-ALLO1, an investigational stem cell memory T cell (TSCM)-based allogeneic CAR-T cell therapy in Phase 1/1b clinical development for the treatment of patients with relapsed/refractory multiple myeloma....Poseida's RMAT application was evaluated based on encouraging early data from its ongoing Phase 1 study of P-BCMA-ALLO1, which demonstrated P-BCMA-ALLO1's potential to offer promising efficacy, safety profile and rapid 'off-the-shelf' patient access....The Company will report new clinical data from the P-BCMA-ALLO1 Phase 1 study in an oral session at the 21st International Myeloma Society Annual Meeting, which is being held in Rio de Janeiro from September 25-28, 2024. Additional clinical updates are planned for the second half of 2024..."

FDA event • P1 data • Hematological Malignancies • Multiple Myeloma • Oncology